Cipla Limited and its wholly owned subsidiary Cipla USA Inc., has announced the launch of leuprolide acetate injection depot 22.5mg.
The product was approved by the United States Food and Drug Administration (FDA) based on a New Drug Application (NDA) submitted under the 505(b)(2) regulatory pathway.
Leuprolide acetate injection depot contains 22.5 mg of leuprolide acetate for 3-month administration given as a single dose injection. It is supplied as lyophilized microspheres in a single dose vial as a kit with a prefilled syringe containing 2ml 0.8% mannitol solution and an easy-to-use Mixject transfer device for a single dose injection. It is indicated for palliative treatment of advanced prostate cancer.
Arunesh Verma, CEO
